Provided by Tiger Fintech (Singapore) Pte. Ltd.

Entrada Therapeutics, Inc.

6.97
-0.2600-3.60%
Post-market: 6.970.00000.00%16:50 EDT
Volume:149.40K
Turnover:1.04M
Market Cap:264.54M
PE:11.49
High:7.19
Open:7.11
Low:6.87
Close:7.23
Loading ...

Entrada Therapeutics Receives Buy Rating Amid Regulatory Progress and Promising Clinical Developments

TIPRANKS
·
25 Feb

Optimistic Outlook on Entrada Therapeutics: FDA Lifts Hold on ENTR-601-44, Paving Way for Key Trials

TIPRANKS
·
25 Feb

BUZZ-U.S. STOCKS ON THE MOVE-BioMarin, Azul, Sun Communities

Reuters
·
24 Feb

BUZZ-U.S. STOCKS ON THE MOVE- Twilio, Bath & Body Works, Wingstop

Reuters
·
24 Feb

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday

MT Newswires Live
·
24 Feb

Entrada Therapeutics Inc (TRDA) Receives a Buy from Roth MKM

TIPRANKS
·
24 Feb

BUZZ-Entrada rises as FDA removes clinical hold on muscle-wasting therapy

Reuters
·
24 Feb

Entrada Therapeutics Says FDA Lifted Clinical Hold on ENTR-601-44; Shares Advance Premarket

MT Newswires Live
·
24 Feb

Entrada Shares Climb After FDA Removes Hold on Muscular Dystrophy Treatment

Dow Jones
·
24 Feb

Entrada Therapeutics Announces FDA Removal of Clinical Hold on Entr-601-44

THOMSON REUTERS
·
24 Feb

Entrada Therapeutics Inc - Study Enrollment to Begin in First Half of 2026

THOMSON REUTERS
·
24 Feb

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

GlobeNewswire
·
24 Feb

Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now

Insider Monkey
·
12 Feb

Entrada Therapeutics Inc.: Promising Therapeutic Potential and Favorable Valuation Amidst Risks

TIPRANKS
·
04 Feb

Entrada Therapeutics Gets UK Approval for Phase 1/2 Study of Duchenne Muscular Dystrophy Treatment

MT Newswires Live
·
04 Feb

Entrada receives authorization from UK MHRA to initiate ELEVATE-44-201

TIPRANKS
·
03 Feb

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Elevate-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of Entr-601-44 in Patients Living With Duchenne Muscular Dystrophy

THOMSON REUTERS
·
03 Feb

Entrada Therapeutics Inc - to Initiate Elevate-44-201 Study in Q2 2025

THOMSON REUTERS
·
03 Feb

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

GlobeNewswire
·
03 Feb

Azenta Announces the Election of Dipal Doshi to Its Board of Directors

THOMSON REUTERS
·
31 Jan